ClinicalTrials.gg
RecruitingNCT05878236MoSAICUpdated Nov 16, 2026

iMmune SignAtures and Clinical outComes in AP

An observational study in Acute Pancreatitis, sponsored by Ohio State University. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Ohio State University · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Nov 16, 2026Enrollment updatedSponsor changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.

Planned enrollment
27th of 41
180 · median 433
Started
2023
with 9 others
Observational
42 of 139
15 open now
Primary completion
2026-12
later than 11 of 48 live
Registered
113th of 139
by date

Among the 139 studies in Pancreatitis with a site in United States, this one is the 27th largest by planned enrollment of the 41 observational ones that give a count, is one of 10 that started in 2023, is one of 42 observational ones, reaches primary completion later than 11 of the 48 other live ones, and was the 113th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Pancreatitis with a site in United States, or all of them as a file.
02

Study summary

The MoSAIC study is a prospective, observational study designed to develop an early prediction tool for severe acute pancreatitis (SAP) and define a distinct immunologic profile compared to moderate acute pancreatitis (MAP). The aims are to validate a new multi-cytokine panel for early prediction of SAP and to identify the specific immune cells that correspond with cytokine signatures in early acute pancreatitis to characterize the immune pathways driving the development of SAP. Participants will provide blood samples and complete patient surveys and interviews within 36 hours of hospital presentation, at 48 hours, and hospital day 7 (if admitted). Data on hospital stay, medical history, clinical course, and severity of disease will be collected.

Read the detailed description

All participants will sign an informed consent before participating in the study. Adult subjects of both sexes and belonging to all ethnicities will be enrolled. Participants will consent for access to their electronic health records, complete study questionnaires, undergo serial clinical laboratory testing and provide biospecimens during their acute pancreatitis (AP) hospitalization. The research team will access the electronic health records for 5 years from the time of enrollment in the study.

The study network is comprised of five academic sites. Four sites will enroll AP patients [OSU, University of Illinois in Chicago Hospital (UIC), University of Pittsburgh Medical Center (UPMC), and the Keck Hospital of the University of Southern California (USC)]. The fifth site, the Benaroya Research Institute (BRI) will coordinate biospecimen handling for analyses, perform bioinformatics and serve as the biospecimen coordinating center (BCC). Each enrolling site will collect and ship biosamples to BRI. The blood samples collected in this study will be deposited into the Benaroya Research Institute (BRI) Immune-Mediated Diseases Registry and Repository (IMDRR). Participation in the repository is a requirement for inclusion in the study. Specimens collected in this study will be used for immune assays. Samples will also be coded and stored for up to 15 years in the IMDRR. Samples may be used to evaluate additional responses as new research tools become available or exploratory hypotheses are generated. OSU will serve as the data coordinating center (DCC). Coordinators at enrolling sites will enter study data into a secure cloud-based electronic database, and the DCC will be in charge of monitoring the quality and completeness of the electronic data.

03

Conditions studied

  • Acute Pancreatitis

Browse trials for

Keywords

  • Acute Pancreatitis
  • Immunology
  • MoSAIC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants who meet all inclusion and no exclusion criteria will be considered for enrollment. Patients presenting to the hospital or emergency room with acute pancreatitis (AP) will be screened and enrolled within 36 hours of presentation to capture relevant biomarker information as early in their episode of AP as possible. Patients with chronic calcific pancreatitis, severe systemic illness confounding severity assessments or immunological outcomes, or anyone with an altered or compromised immune system will be excluded from enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years at the time of enrollment
  2. Diagnosis of acute pancreatitis (AP) according to the revised Atlanta criteria (see definition below)
  3. Participant is approached by the research team within 36 hours of presentation to the hospital
  4. Participant fully understands and agrees to participate in all aspects of the study, including providing , completion of interviews and data forms, and collection of biospecimens

Acute pancreatitis is defined/diagnosed using the revised Atlanta criteria, which requires the presence of at least two of the following criteria:

i. Upper abdominal pain ii. Elevation of serum amylase or lipase level to >/=3 times the iii. Features of AP on cross-sectional imaging.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of definite chronic pancreatitis (CP) at enrollment (see also study definitions) based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP):

    i. Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular) ii. Intraductal filling defects suggestive of calcifications on MRI and/or MRCP iii. Non-contrast imaging is acceptable for the assessment of definite CP, but calcifications noted by endoscopic ultrasound only (and not correlated with CT) are not considered definite CP. Patients with pancreatitis, but no evidence of calcifications, may still be enrolled, assuming they satisfy inclusion criteria for 'diagnosis of AP'

  2. Potential participants with post-ERCP AP who are expected to be hospitalized for less than 48 hours.
  3. Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and .
  4. Confirmed or suspected cystic tumor associated with main pancreatic duct dilation or believed to be the cause of AP (in the site-PI's judgment).
  5. Prior pancreatic surgery, including, but not limited to distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, and Frey procedure.
  6. Severe systemic illness that in the judgment of the investigative team will confound outcome assessments and immunological outcomes or pose additional risk for harm, including the history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with \<30 or on dialysis prior to AP, and cirrhosis (based on imaging or ), or any other medical condition that in the opinion of the site-PI carries a of \<12 months.
  7. Known pregnancy at the time of enrollment.
  8. Incarceration.
  9. Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Acute Pancreatitis

    Patients meeting Revised Atlanta Criteria for diagnosis of acute pancreatitis

    Diagnostic Test: CyTOF Analysis

Interventions

  • Diagnostic testCyTOF Analysis

    CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis

06

What researchers measure

Primary outcomes

  1. Multi-Cytokine Panel Validation

    Validate a novel multi-cytokine panel for early prediction of severe acute pancreatitis. The panel includes IL-8, TNFa R1, HGF, Resistin and Angiopoietin-2.

    Time frame: 4 years

  2. Cytokine Signature Correlation

    Correlate temporal cytokine signatures with disease severity. We will be correlating the above cytokines as well Il-6 and MCP-1.

    Time frame: 4 years

Secondary outcomes

  1. Circulating Immune Cells

    Identify circulating immune cells that correspond with cytokine signatures in early acute pancreatitis

    Time frame: 4 years

  2. Immune Pathways

    Characterize the immune pathways driving the development of severe acute pancreatitis

    Time frame: 4 years

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 82 non-industry observational studies under Pancreatitis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 133. This study's planned 45 months is close to that.

Counting every sponsor, half of 86 studies reached it within 50 months; a quarter within 21 and three quarters within 133.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Dec 2028, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
May 26, 2023
StartActual
Mar 6, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028was Dec 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 31, 2027→Dec 31, 2028
Oct 16, 2026
Enrollment
198→180
Nov 16, 2026
Sponsor
Collaborators added: University of Illinois Chicago; collaborators removed: University of Illinois at Chicago
Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Enrollment 198→180
    Sponsor Collaborators added: University of Illinois Chicago; collaborators removed: University of Illinois at Chicago
  2. Oct 16, 2026
    Study completion Dec 31, 2027→Dec 31, 2028
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05878236
Collaborators
University of Pittsburgh, University of Illinois Chicago, University of Southern California, Benaroya Research Institute
Responsible party
George Papachristou (Professor of Internal Medicine, Director of Gastroenterology, Ohio State University) — Principal investigator
First posted
May 26, 2023
Start date
Mar 6, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Zoe Krebs, BA
Contact
zoe.krebs@osumc.edu
614-685-3619
Samantha Terhorst, MS
Contact
samantha.terhorst@osumc.edu
614-685-3618

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion